ES2335475T3 - Formulacion de acido 5-aminolevulinico en dosolventes no acuosos. - Google Patents
Formulacion de acido 5-aminolevulinico en dosolventes no acuosos. Download PDFInfo
- Publication number
- ES2335475T3 ES2335475T3 ES01911547T ES01911547T ES2335475T3 ES 2335475 T3 ES2335475 T3 ES 2335475T3 ES 01911547 T ES01911547 T ES 01911547T ES 01911547 T ES01911547 T ES 01911547T ES 2335475 T3 ES2335475 T3 ES 2335475T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- ala
- composition according
- kit
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 title claims abstract description 63
- 229960002749 aminolevulinic acid Drugs 0.000 title claims abstract description 63
- 238000009472 formulation Methods 0.000 title description 6
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 239000013543 active substance Substances 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000002428 photodynamic therapy Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 8
- 150000002085 enols Chemical group 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 230000000699 topical effect Effects 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 230000006641 stabilisation Effects 0.000 claims description 4
- 238000011105 stabilization Methods 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000012062 aqueous buffer Substances 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010059313 Anogenital warts Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 208000013165 Bowen disease Diseases 0.000 claims description 2
- 208000019337 Bowen disease of the skin Diseases 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000004530 micro-emulsion Substances 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 1
- 230000000711 cancerogenic effect Effects 0.000 claims 1
- 231100000315 carcinogenic Toxicity 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 239000003504 photosensitizing agent Substances 0.000 abstract description 12
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 abstract description 9
- 229950003776 protoporphyrin Drugs 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- -1 alcohols C 1 -C 20 Chemical class 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000002262 Schiff base Substances 0.000 description 4
- 150000004753 Schiff bases Chemical class 0.000 description 4
- 239000008135 aqueous vehicle Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000007857 degradation product Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 150000003278 haem Chemical class 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- CIGLZLCKRXOFQU-UHFFFAOYSA-N 1,4-dihydropyrazine-2,3-dione Chemical class O=C1NC=CNC1=O CIGLZLCKRXOFQU-UHFFFAOYSA-N 0.000 description 2
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- QSHWIQZFGQKFMA-UHFFFAOYSA-N Porphobilinogen Natural products NCC=1NC=C(CCC(O)=O)C=1CC(O)=O QSHWIQZFGQKFMA-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- YPHQRHBJEUDWJW-UHFFFAOYSA-N porphobilinogen Chemical compound NCC1=NC=C(CCC(O)=O)[C]1CC(O)=O YPHQRHBJEUDWJW-UHFFFAOYSA-N 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 230000008844 regulatory mechanism Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical class CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- 229950008441 clofibric acid Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005837 enolization reaction Methods 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002186 photoactivation Effects 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10003620A DE10003620A1 (de) | 2000-01-28 | 2000-01-28 | 5-Aminolävulinsäure-Formulierung in nichtwässrigen Lösungsmitteln |
| DE10003620 | 2000-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2335475T3 true ES2335475T3 (es) | 2010-03-29 |
Family
ID=7628975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01911547T Expired - Lifetime ES2335475T3 (es) | 2000-01-28 | 2001-01-29 | Formulacion de acido 5-aminolevulinico en dosolventes no acuosos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20030125388A1 (de) |
| EP (1) | EP1255725B1 (de) |
| JP (1) | JP2003526637A (de) |
| AT (1) | ATE455090T1 (de) |
| AU (1) | AU2001240556A1 (de) |
| CA (1) | CA2399405C (de) |
| CY (1) | CY1109948T1 (de) |
| DE (2) | DE10003620A1 (de) |
| DK (1) | DK1255725T3 (de) |
| ES (1) | ES2335475T3 (de) |
| PT (1) | PT1255725E (de) |
| WO (1) | WO2001055092A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2248536A3 (de) * | 2000-12-14 | 2010-12-08 | The General Hospital Corporation doing business as Massachusetts General Hospital | Topische aminolevulinsäure-photodynamische therapie für akne vulgaris |
| WO2002013788A1 (en) | 2000-08-16 | 2002-02-21 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Topical aminolevulinic acid-photodynamic therapy for acne vulgaris |
| DE10301917B4 (de) * | 2003-01-17 | 2007-02-01 | Gerhard Saalmann | Verwendung von Substanzen der Porphyrinsynthese bei der Phototherapie von Haut- oder Gelenkerkrankungen des Menschen oder von Säugetieren |
| GB0424833D0 (en) | 2004-11-10 | 2004-12-15 | Photocure Asa | Method |
| US8419341B2 (en) | 2006-09-19 | 2013-04-16 | Brooks Automation, Inc. | Linear vacuum robot with Z motion and articulated arm |
| EP1938801A1 (de) * | 2006-12-22 | 2008-07-02 | Biofrontera Bioscience GmbH | Nanoemulsion |
| WO2008106966A1 (en) * | 2007-03-06 | 2008-09-12 | Christiansen Kaare | A method for non-therapeutic or therapeutic photodynamic skin treatment |
| CA2724949A1 (en) | 2007-06-27 | 2008-12-31 | The General Hospital Corporation | Method and apparatus for optical inhibition of photodynamic therapy |
| GB0724279D0 (en) * | 2007-12-12 | 2008-01-23 | Photocure Asa | Use |
| JP5081121B2 (ja) * | 2008-10-17 | 2012-11-21 | 株式会社ミルボン | 育毛剤組成物 |
| EP2440188A1 (de) * | 2009-06-11 | 2012-04-18 | Photocure ASA | Feste zusammensetzungen mit 5-aminolävulinsäure |
| US20120136055A1 (en) * | 2009-06-11 | 2012-05-31 | Photocure Asa | Semi-solid compositions and pharmaceutical products |
| JP5574329B2 (ja) * | 2010-05-06 | 2014-08-20 | 国立大学法人 岡山大学 | ミトコンドリアの蛍光染色方法 |
| CN103270168A (zh) | 2010-12-24 | 2013-08-28 | 爱科来株式会社 | 癌细胞的检测方法 |
| CN112010772A (zh) | 2016-01-26 | 2020-12-01 | 赵鸣 | 5-氨基酮戊酸及其衍生物的盐化合物和应用 |
| ES2638239B1 (es) * | 2016-03-18 | 2018-08-09 | Consejo Superior De Investigaciones Científicas (Csic) | Procedimiento de monitorización de digestores anaerobios |
| CN108434100A (zh) * | 2018-04-27 | 2018-08-24 | 中南大学湘雅三医院 | 一种用于光动力疗法治疗鼻咽喉腔疾病的喷雾光敏剂组合物 |
| WO2023180282A1 (en) | 2022-03-24 | 2023-09-28 | Evonik Operations Gmbh | Co-precipitates of methionylmethionine with organic compounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US5026825A (en) * | 1988-09-08 | 1991-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Intranasal calcitonin formulations |
| DE4320871C2 (de) * | 1993-06-24 | 1995-05-04 | Beiersdorf Ag | Kosmetische und dermatologische Zubereitungen mit einem Gehalt an delta-Aminolävulinsäure |
| EP0704209A1 (de) * | 1994-09-20 | 1996-04-03 | JOHNSON & JOHNSON MEDICAL, INC. | Transdermal aktive pharmazeutische Zusammensetzung enthaltend 5-Aminolaevulinsäure |
| HU225148B1 (en) * | 1995-03-10 | 2006-07-28 | Photocure Asa | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy or diagnosis, products and kits comprising thereof and method of in vitro diagnosis by their using |
| JP3644809B2 (ja) * | 1997-10-15 | 2005-05-11 | コスモ石油株式会社 | 頭部用外用剤 |
| US5954703A (en) * | 1997-10-31 | 1999-09-21 | Dusa Pharmaceuticals, Inc. | Method and apparatus for applying 5-aminolevulinic acid |
| FR2777782B1 (fr) * | 1998-04-22 | 2001-05-18 | Alexandre Marti | Solution pour la preparation d'une substance pharmaceutique pour le diagnostic et/ou le traitement de lesions tissulaires |
-
2000
- 2000-01-28 DE DE10003620A patent/DE10003620A1/de not_active Withdrawn
-
2001
- 2001-01-29 AT AT01911547T patent/ATE455090T1/de active
- 2001-01-29 PT PT01911547T patent/PT1255725E/pt unknown
- 2001-01-29 JP JP2001555035A patent/JP2003526637A/ja active Pending
- 2001-01-29 ES ES01911547T patent/ES2335475T3/es not_active Expired - Lifetime
- 2001-01-29 AU AU2001240556A patent/AU2001240556A1/en not_active Abandoned
- 2001-01-29 DK DK01911547.6T patent/DK1255725T3/da active
- 2001-01-29 WO PCT/EP2001/000930 patent/WO2001055092A2/de active Application Filing
- 2001-01-29 US US10/182,535 patent/US20030125388A1/en not_active Abandoned
- 2001-01-29 DE DE50115306T patent/DE50115306D1/de not_active Expired - Lifetime
- 2001-01-29 CA CA2399405A patent/CA2399405C/en not_active Expired - Fee Related
- 2001-01-29 EP EP01911547A patent/EP1255725B1/de not_active Revoked
-
2010
- 2010-04-06 CY CY20101100313T patent/CY1109948T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1255725A2 (de) | 2002-11-13 |
| AU2001240556A1 (en) | 2001-08-07 |
| WO2001055092A3 (de) | 2002-02-14 |
| WO2001055092B1 (de) | 2002-03-07 |
| DE50115306D1 (de) | 2010-03-04 |
| DK1255725T3 (da) | 2010-04-26 |
| EP1255725B1 (de) | 2010-01-13 |
| DE10003620A1 (de) | 2001-08-02 |
| PT1255725E (pt) | 2010-03-31 |
| CY1109948T1 (el) | 2014-09-10 |
| CA2399405A1 (en) | 2001-08-02 |
| WO2001055092A2 (de) | 2001-08-02 |
| CA2399405C (en) | 2010-03-23 |
| ATE455090T1 (de) | 2010-01-15 |
| US20030125388A1 (en) | 2003-07-03 |
| JP2003526637A (ja) | 2003-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2335475T3 (es) | Formulacion de acido 5-aminolevulinico en dosolventes no acuosos. | |
| Zhu et al. | 5‐Aminolevulinic acid‐loaded hyaluronic acid dissolving microneedles for effective photodynamic therapy of superficial tumors with enhanced long‐term stability | |
| Shemesh et al. | Thermosensitive liposome formulated indocyanine green for near-infrared triggered photodynamic therapy: in vivo evaluation for triple-negative breast cancer | |
| AU758098B2 (en) | Nano-emulsion of 5-aminolevulinic acid | |
| ES2346289T3 (es) | Medicamentos para el tratamiento fotodinamico de enfermedades. | |
| US20130330244A1 (en) | Compositions and methods for topical nitric oxide generation | |
| US20120283328A1 (en) | Photosensitizer composition for treating skin disorders | |
| EP2020242A2 (de) | Verbesserte topische Medikamente und Verfahren zur photodynamischen Krankheitsbehandlung | |
| CN106187793A (zh) | 5‑氨基酮戊酸及其衍生物的盐化合物和应用 | |
| Ji et al. | External stimuli-responsive gasotransmitter prodrugs: Chemistry and spatiotemporal release | |
| US6790463B2 (en) | Uses of targeted oxidative therapeutic formulation in arteriosclerosis | |
| US8609677B2 (en) | Molecules for the photodynamic treatment of tumors and hyperplasias | |
| ES2283406T3 (es) | Medicamentos intracorporeos para tratamiento fototerapeutico de alta energia de enfermedad. | |
| ES2623857T3 (es) | 5-(Aziridin-1-il)-4-hidroxilamin-2-nitrobenzamida y su uso en medicina | |
| Donnelly et al. | Photosensitiser delivery for photodynamic therapy. Part 1: Topical carrier platforms | |
| De Blois et al. | In vivo pharmacokinetics of protoporphyrin IX accumulation following intracutaneous injection of 5-aminolevulinic acid | |
| US10716805B2 (en) | Formulation for release of nitric oxide | |
| KR20220066068A (ko) | 활성 제제의 국소 전달을 위한 용매 전달 시스템 | |
| ES2371948T3 (es) | Medicamentos tópicos mejorados y métodos para el tratamiento fotodinámico de una enfermedad. | |
| CA3055882A1 (en) | Topical formulation for the treatment of pigmented skin | |
| ITMI20011321A1 (it) | Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del | |
| CA3055881A1 (en) | Use of heterocyclic compounds in the treatment of pigmented skin | |
| KR101315133B1 (ko) | 인돌-3-아세트산을 포함하는 주사증 치료용 약학적 조성물 및 광역학 키트 | |
| RomiszewskA et al. | The use of 5-aminolevulinic acid and its derivatives in photodynamic therapy and diagnosis | |
| WO2006085517A1 (ja) | クロリン類及びポルフィリン類のｐｄｔ用軟膏製剤及び坐剤 |